Combining the corticosteroid methylprednisolone and Jakafi (ruxolitinib), an approved oral therapy for bone marrow disorders, is showing promising effectiveness in heavily pre-treated multiple myeloma patients in an ongoing Phase 1 trial. Findings to date from this open-label study (NCT03110822), which is being sponsored by Onco Therapeutics, showed that the combination not only elicited promising responses but was also capable of restoring sensitivity to Revlimid (lenalidomide), an approved immunomodulatory agent. “Besides having a direct MM [multiple myeloma] killing…
You must be logged in to read/download the full post.
The post Jakafi Plus Steroid Continuing to Treat Multiple Myeloma in Phase 1 Trial appeared first on BioNewsFeeds.